Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | FPR3 | P25089 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | GPR183 | P32249 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688153 | 1.00 | P2RY12 (0.46) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL29688349 | 0.95 | P2RY12 (0.42) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL3615225 | 0.95 | P2RY12 (0.42) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL6619644 | 0.92 | P2RY12 (0.50) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL3615932 | 0.84 | P2RY12 (0.31) | P2RY12 | |
| SCHEMBL14781568 | 0.79 | P2RY12 (0.71) | P2RY12CYP2C9PGRADORA3CHRM1 | |
| SCHEMBL14900240 | 0.78 | P2RY12 (0.44) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL19712299 | 0.78 | P2RY12 (0.44) | P2RY12CYP2C9 | |
| SCHEMBL15757983 | 0.78 | P2RY12 (0.43) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL1509197 | 0.78 | P2RY12 (0.43) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46276-E1 | Triazolo(4,5-D)pyrimidine compounds | ASTRAZENECA UK LIMITED (GB) | 2017-01-17 | — | — | US | claimed |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA UK LIMITED (GB) | 2015-06-04 | — | — | US | claimed |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA AB (GB) | 2013-05-02 | — | — | US | claimed |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | ASTRAZENECA (GB) | 2013-03-21 | — | — | US | claimed |
| US-20120165348-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | claimed |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | claimed |
| EP-1135391-B1 | NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | claimed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | claimed |
| US-6525060-B1 | P2T (P2YADP or P2TAC) receptor antagonists; anticoagulant, antithrombotic | ASTRAZENECA UK LIMITED (GB) | 2003-02-25 | — | — | US | claimed |
| US-10614684-B2 | Treatment of kidney diseases associated with elevated AVP | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20180214450-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165348-A1 | Novel compounds | P2RX5, P2RX4, P2RY4 | P2RY12 25/4885CYP2C9 834/4885PGR 1682/4885 |
| US-10614684-B2 | Treatment of kidney diseases associated with elevated AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885CYP2C9 2181/4885PGR 1851/4885 |
| US-20180214450-A1 | TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP | AVPR2, PKD1, AVPR1A | P2RY12 321/4885CYP2C9 2181/4885PGR 1851/4885 |
| US-20150152111-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | P2RY12 12/4885CYP2C9 460/4885PGR 1409/4885 |
| US-20100069408-A1 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition | THPO, PF4, P2RY4 | P2RY12 12/4885CYP2C9 460/4885PGR 1409/4885 |
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | P2RY12 72/4885CYP2C9 718/4885PGR 2189/4885 |
| US-20130072503-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | P2RY12 12/4885CYP2C9 460/4885PGR 1409/4885 |
| US-20130109702-A1 | TRISUBSTITUTED TRIAZOLOPYRIMIDINES FOR USE IN PLATELET AGGREGATION INHIBITION | THPO, PF4, P2RY4 | P2RY12 12/4885CYP2C9 460/4885PGR 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.